BrainsWay Ltd. (BWAY)
- Previous Close
4.8000 - Open
4.7300 - Bid 4.6800 x 100
- Ask 4.8900 x 100
- Day's Range
4.7200 - 4.8700 - 52 Week Range
1.3800 - 7.6150 - Volume
30,821 - Avg. Volume
102,982 - Market Cap (intraday)
79.192M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.85
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
www.brainsway.comRecent News: BWAY
Performance Overview: BWAY
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BWAY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BWAY
Valuation Measures
Market Cap
84.00M
Enterprise Value
38.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.48
Price/Book (mrq)
1.90
Enterprise Value/Revenue
1.21
Enterprise Value/EBITDA
-15.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.20%
Return on Assets (ttm)
-4.86%
Return on Equity (ttm)
-9.65%
Revenue (ttm)
31.79M
Net Income Avi to Common (ttm)
-4.2M
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
45.98M
Total Debt/Equity (mrq)
1.13%
Levered Free Cash Flow (ttm)
-1.65M